Juno Therapeutics Inc (JUNO) Receives $57.93 Average Target Price from Brokerages

Juno Therapeutics Inc (NASDAQ:JUNO) has received an average rating of “Hold” from the twenty-one research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eighteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $57.93.

JUNO has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Citigroup downgraded shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 17th. Leerink Swann downgraded shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and raised their target price for the company from $56.00 to $87.00 in a research note on Tuesday, January 23rd. Finally, Guggenheim downgraded shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd.

In other Juno Therapeutics news, EVP Robert Azelby sold 102,539 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75. Following the transaction, the executive vice president now directly owns 173,371 shares in the company, valued at $14,953,248.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 114,360 shares of company stock worth $9,857,003 over the last quarter. Company insiders own 15.08% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Comerica Bank bought a new position in Juno Therapeutics during the fourth quarter valued at approximately $240,000. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares during the last quarter. Advisor Group Inc. grew its holdings in shares of Juno Therapeutics by 53.0% in the fourth quarter. Advisor Group Inc. now owns 3,763 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 1,304 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Juno Therapeutics in the fourth quarter worth approximately $173,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Juno Therapeutics in the fourth quarter worth approximately $209,000. Institutional investors and hedge funds own 70.19% of the company’s stock.

JUNO remained flat at $$86.96 on Wednesday. 2 shares of the company were exchanged, compared to its average volume of 5,484,542. The company has a current ratio of 3.61, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 1-year low of $19.62 and a 1-year high of $87.01.

COPYRIGHT VIOLATION WARNING: “Juno Therapeutics Inc (JUNO) Receives $57.93 Average Target Price from Brokerages” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3377231/juno-therapeutics-inc-juno-receives-57-93-average-target-price-from-brokerages.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stevens Capital Management LP Takes $955,000 Position in Owens Corning
Stevens Capital Management LP Takes $955,000 Position in Owens Corning
Financial Survey: Omnicom Group  and WPP
Financial Survey: Omnicom Group and WPP
Sierra Wireless  Receives $24.30 Consensus PT from Analysts
Sierra Wireless Receives $24.30 Consensus PT from Analysts
JPMorgan Chase  Receives $112.96 Consensus PT from Brokerages
JPMorgan Chase Receives $112.96 Consensus PT from Brokerages
Colfax Co.  Receives $36.73 Consensus PT from Analysts
Colfax Co. Receives $36.73 Consensus PT from Analysts
Biofrontera  and Its Rivals Financial Survey
Biofrontera and Its Rivals Financial Survey


© 2006-2018 Ticker Report. Google+.